Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
„Sopharma” AD (the Company) notifies that for July 2022 the Company recorded an increase in sales of 146% compared to the same month of the previous year, incl. 96% increase in domestic sales and 206% increase in export sales.
For the seven months since the beginning of the year the revenues from sales of products increase by 46%, incl. 42% increase of sales for the domestic market and 49% increase in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
Treść pochodzi z serwisu: pap-mediaroom.pl
